Investor Relations Event to Enhance Understanding: Updates on Knee Osteoarthritis Drug OSCA Clinical Trials and Organoid Business

KANGSTEM BIOTECH will hold an Investor Relations (IR) event on June 10, 2026, from 14:00 to 15:30 at Ruby Hall, 2F FKI Tower, Yeouido, Seoul, targeting individual and institutional investors.
Key topics include the status and future plans for the Phase 2a trial of knee osteoarthritis drug OSCA, recent long-term follow-up results from Phase 1, and clinical research progress under the Advanced Regenerative Medicine Act.
Updates on the domestic and international progress and strategy of the organoid new business, as well as global licensing-out progress, will also be presented.
[AI Summary]This IR is a routine event for communicating drug development and business progress to investors, with no specific positive or negative impact. It does not directly affect the stock price outlook and is considered neutral in terms of reducing information asymmetry.